Breaking News Instant updates and real-time market news.

BIIB

Biogen

$225.94

-3.11 (-1.36%)

, NVS

Novartis

$87.93

3.47 (4.11%)

14:25
05/24/19
05/24
14:25
05/24/19
14:25

Zolgensma label breadth on higher end of expectations, says Credit Suisse

Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.

BIIB

Biogen

$225.94

-3.11 (-1.36%)

NVS

Novartis

$87.93

3.47 (4.11%)

  • 29

    May

  • 31

    May

  • 05

    Jun

BIIB Biogen
$225.94

-3.11 (-1.36%)

05/20/19
FBCO
05/20/19
INITIATION
FBCO
Underperform
Biogen initiated with an Underperform at Credit Suisse
Credit Suisse analyst Evan Seigerman initiated Biogen with an Underperform rating and $198 price target, saying that "life beyond aducanumab will likely remain challenging for Biogen" with the company's core base business "likely to decline in the near term with a weak pipeline that will not likely be able to yield revenue and earnings growth." While Seigerman said that Biogen's MS business is stable, he noted that headwinds are mounting.
05/22/19
WEDB
05/22/19
INITIATION
Target $231
WEDB
Neutral
Biogen initiated with a Neutral at Wedbush
Wedbush analyst Laura Chico started Biogen with a Neutral rating and $231 price target.
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/23/19
05/23/19
INITIATION
Target $231

Neutral
Biogen initiated with a Neutral at Wedbush
As previously reported, Wedbush analyst Laura Chico started Biogen with a Neutral rating and a $231 price target. The analyst says the company is "at a crossroads" as it looks to move on from its recent aducanumab Alzheimer's disease setback, noting that few of its early-stage pipeline assets appear to be positioned to make a near-term impact on its top line. Chico further warns that inter partes review of Biogen's Tecfidera patent could lead to generic competition sooner than expected.
NVS Novartis
$87.93

3.47 (4.11%)

05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
06/19/19
06/19
13:17
06/19/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
06/19/19
06/19
13:16
06/19/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$42.95

-0.27 (-0.62%)

13:15
06/19/19
06/19
13:15
06/19/19
13:15
Options
BNY Mellon put volume heavy and directionally bearish »

Bearish flow noted in BNY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

RIO

Rio Tinto

$59.44

-2.745 (-4.41%)

13:06
06/19/19
06/19
13:06
06/19/19
13:06
Hot Stocks
Rio Tinto drops over 4% after reporting operational challenges »

Earlier today, Rio Tinto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$116.95

0.28 (0.24%)

13:03
06/19/19
06/19
13:03
06/19/19
13:03
Hot Stocks
California American Water desalination project wins $10M state grant »

The California Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$11.62

-0.435 (-3.61%)

13:02
06/19/19
06/19
13:02
06/19/19
13:02
Hot Stocks
MGA calls off Mattel merger talks, says 'too much mess to clean up' »

MGA Entertainment CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$8.30

-0.045 (-0.54%)

13:01
06/19/19
06/19
13:01
06/19/19
13:01
Hot Stocks
Teva announces U.S. launch of generic version of Tracleer »

Teva Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Z

Zillow

$45.36

-1.1 (-2.37%)

13:00
06/19/19
06/19
13:00
06/19/19
13:00
Options
Zillow put buyer opens new short-term position »

Zillow put buyer opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$11.62

-0.43 (-3.57%)

12:59
06/19/19
06/19
12:59
06/19/19
12:59
Hot Stocks
Breaking Hot Stocks news story on Mattel »

MGA Entertainment CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHS

Chico's

$3.24

0.14 (4.52%)

12:56
06/19/19
06/19
12:56
06/19/19
12:56
Hot Stocks
Sycamore Partners lowers takeover offer to Chico's to $3.00 per share »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBAY

CymaBay

$7.00

-0.09 (-1.27%)

12:55
06/19/19
06/19
12:55
06/19/19
12:55
Options
CymaBay put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$11.58

-0.47 (-3.90%)

12:55
06/19/19
06/19
12:55
06/19/19
12:55
Hot Stocks
Breaking Hot Stocks news story on Mattel »

MGA Entertainment says no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$23.93

0.57 (2.44%)

12:50
06/19/19
06/19
12:50
06/19/19
12:50
Periodicals
KKR close to selling partial stake in $2B helicopter firm, Bloomberg says »

According to Elffie Chew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHS

Chico's

$3.24

0.14 (4.52%)

12:49
06/19/19
06/19
12:49
06/19/19
12:49
Hot Stocks
Chico's erases gains after Bloomberg says Sycamore again lowered bid »

Chico's in midday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHS

Chico's

$3.25

0.145 (4.68%)

12:48
06/19/19
06/19
12:48
06/19/19
12:48
Periodicals
Sycamore Partners lowers bid for Chico's to $3 per share, Bloomberg reports »

Sycamore Partners has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$52.59

0.15 (0.29%)

12:45
06/19/19
06/19
12:45
06/19/19
12:45
Options
General Mills call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 09

    Jul

  • 10

    Jul

  • 11

    Jul

BIDU

Baidu

$117.13

0.26 (0.22%)

12:41
06/19/19
06/19
12:41
06/19/19
12:41
Periodicals
Baidu says Apollo Lite framework achieves level 4 autonomy, VB reports »

According to VB's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

KR

Kroger

$23.62

-0.32 (-1.34%)

, DRI

Darden

$116.14

-1.8 (-1.53%)

12:35
06/19/19
06/19
12:35
06/19/19
12:35
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$23.62

-0.32 (-1.34%)

DRI

Darden

$116.14

-1.8 (-1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

MDR

McDermott

$7.69

0.065 (0.85%)

12:35
06/19/19
06/19
12:35
06/19/19
12:35
Options
McDermott put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
06/19/19
06/19
12:35
06/19/19
12:35
General news
FOMC forecast preview: »

FOMC forecast preview:…

ORCL

Oracle

$52.80

-0.08 (-0.15%)

12:35
06/19/19
06/19
12:35
06/19/19
12:35
Earnings
Notable companies reporting after market close »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

GME

GameStop

$5.65

-0.08 (-1.40%)

, ATVI

Activision Blizzard

$45.02

-0.76 (-1.66%)

12:33
06/19/19
06/19
12:33
06/19/19
12:33
Hot Stocks
GameStop says new 'Call of Duty' most pre-ordered video game following E3 »

GameStop (GME) said that…

GME

GameStop

$5.65

-0.08 (-1.40%)

ATVI

Activision Blizzard

$45.02

-0.76 (-1.66%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$109.38

-1.61 (-1.45%)

EA

Electronic Arts

$92.38

0.35 (0.38%)

MSFT

Microsoft

$134.54

-0.66 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 23

    Jun

  • 25

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

  • 13

    Nov

INO

Inovio

$2.61

-0.02 (-0.76%)

12:25
06/19/19
06/19
12:25
06/19/19
12:25
Conference/Events
Inovio management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SHOP

Shopify

$316.25

11.94 (3.92%)

12:25
06/19/19
06/19
12:25
06/19/19
12:25
Conference/Events
Shopify to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 05

    Sep

EVBG

Everbridge

$89.89

1.36 (1.54%)

12:25
06/19/19
06/19
12:25
06/19/19
12:25
Conference/Events
Everbridge to host analyst & investor meeting »

Analyst & Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.